

TITAN PHARMACEUTICALS INC  
Form 8-K  
January 03, 2013

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act 1934

Date of Report (Date of earliest event reported): December 31, 2012

## Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware  
(State or Other Jurisdiction of

Incorporation)

400 Oyster Point Blvd., Suite 505, South San Francisco, CA  
(Address of Principal Executive Offices)

0-27436  
(Commission

File Number)

94-3171940  
(IRS Employer

Identification No.)

94080  
(Zip Code)

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

Registrant's telephone number, including area code: 650-244-4990

(Former Name or Former Address, is Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

Titan Pharmaceuticals, Inc. has received notification from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for Probuphine<sup>®</sup> has been accepted for review and granted Priority Review designation by the FDA. Based upon the Prescription Drug User Fee Act, the FDA has set a target date of April 30, 2013 for FDA action on the NDA.

The press release dated January 2, 2013 announcing the Priority Review designation is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release dated January 2, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TITAN PHARMACEUTICALS, INC.

By: /s/ Sunil Bhonsle  
Name: Sunil Bhonsle  
Title: President

Dated: January 2, 2013

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release dated January 2, 2013